ESC Professional Premium Access

Omecamtiv mecarbil for the management of heart failure: a meta-analysis of randomized controlled trials

Congress Session

About the speaker

Doctor Vanessa Hurtado

University Of Miami Hospital, Miami (United States of America)
0 follower

6 more presentations in this session

Adherence and discontinuation of optimal heart failure therapies according to age

Speaker: Miss C. Garred (Gentofte, DK)

Thumbnail

Maximally tolerated guideline-directed medical therapy and barriers to optimization in patients with heart failure with reduced ejection fraction: The COAPT trial

Speaker: Associate Professor Z. Cox (Nashville, US)

Thumbnail

Real-world eligibility for vericiguat according to trial, guideline, and labelling eligibility criteria: data from the Swedish Heart Failure Registry

Speaker: Mr V. Nguyen (Stockholm, SE)

Thumbnail

Efficacy of sodium glucose cotransporter 2 inhibitors for heart failure with preserved and mildly reduced ejection fraction: a systematic review and meta-analysis

Speaker: Doctor K. Rivera (Metro Manila, PH)

Thumbnail

Compliance to guideline-recommended pharmacotherapy in patients with heart failure, 2014 to 2020

Speaker: Doctor K. Odegaard (Oslo, NO)

Thumbnail

Access the full session

Heart failure pharmacology

Speakers: Doctor V. Hurtado, Miss C. Garred, Associate Professor Z. Cox, Mr V. Nguyen, Doctor K. Rivera...
Thumbnail

About the event

Image

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

This platform is supported by

logo Novo Nordisk